Innocan Pharma Moves Forward with Share Consolidation for U.S. Offering

Innocan Pharma's Strategic Share Consolidation

Innocan Pharma Corporation, known for its innovative contributions to the pharmaceutical market, has officially announced a significant move aimed at strengthening its position for future offerings. In a press release dated August 29, 2025, Innocan outlined the crucial details regarding its proposed share consolidation. This step is pivotal as the company prepares for a public offering in the United States and aims to list its common shares on the NASDAQ Capital Market.

The consolidation entails transforming the company's current share count, where every 65 shares will be consolidated into one new post-consolidation share. This reduction in the overall number of shares aims not only to enhance share value but also to meet NASDAQ listing requirements. According to Iris Bincovich, CEO of Innocan, this consolidation is part of a broader strategy intended to facilitate the company’s ambitions of a NASDAQ presence and attract potential investors.

Details of the Share Consolidation

At the Company’s recent annual meeting, shareholders approved a consolidation ratio of one post-consolidation share for every 100 pre-consolidation shares, leaving the Board of Directors to exercise discretion on the exact ratio. Ultimately, the Board set a final consolidation ratio at 65:1.

Projected for September 5, 2025, Innocan anticipates that trading on the post-consolidation basis will commence on the Canadian Securities Exchange (CSE), subject to CSE approval. This recalibration will reduce the existing approximately 292 million common shares down to roughly 4.5 million shares after the consolidation, with shares being rounded post-consolidation to eliminate fractional issues.

Upon completion of the consolidation, shareholders will receive detailed instructions on exchanging their current shares for the newly consolidated shares, enabling a seamless transition throughout this significant period. However, those holding shares through intermediaries might have a different procedure, emphasizing the importance of communication in share transfer processes.

The Path Forward: U.S. Offering and Investor Engagement

Innocan's journey doesn’t stop at the consolidation. The company has also filed a registration statement with the U.S. Securities and Exchange Commission (SEC) concerning the public offering, which will involve issuing units comprising one share and one share purchase warrant. This strategic maneuver underlines Innocan's commitment to growing its investor base within the increasingly competitive U.S. pharmaceutical landscape.

As Innocan prepares for this offering, ThinkEquity LLC has been designated as the representative underwriter, steering the company through its market navigation. The fulfillment of this offering will be strictly in accordance with regulations, ensuring that all transactions abide by legal requirements.

According to management, despite facing a plethora of uncertainties and market volatility, the company remains optimistically committed to its goals. Innocan's innovative ventures extend beyond the consolidation, with ongoing developments in the wellness and pharmaceutical sectors. Notably, the company has established a CBD-loaded drug delivery platform intended for non-opioid pain management.

Conclusion

In summary, Innocan Pharma Corporation is taking remarkable steps with its proposed share consolidation and anticipated public offering, gearing itself for exciting developments ahead. With the effective execution of strategies tailored to boost its market presence, Innocan is poised to enhance its reputation and drive further success in the pharmaceutical industry. As investors watch keenly, Innocan's ability to adapt and thrive will be intriguing to follow.

For additional information about Innocan and its products, visit Innocan's website.